Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Cabozantinib S-Malate in Treating Patients With Neuroendocrine Tumors

Research Question:
How well does cabozantinib S-malate work compared with placebo in treating patients with neuroendocrine tumors that have spread after previous treatment with everolimus?

Basic Study Information

Purpose:
This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery after previous treatment with everolimus. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Location: University of Rochester Medical Center
Study Reference #: CGIP19127

Lead Researcher (Principal Investigator)

Lead Researcher: Aram Hezel

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search